Depression and immunity: The HCV model

Psychiatria Danubina

Volumn 26, Issue , 2014, Pages 132-137

  Apicella, Emanuela ^a  

^a Clinic for Eating Disorders Villa Miralago   (Italy)

Author keywords

Depression; HCV; Immunity

Indexed keywords

ALPHA INTERFERON; AMFEBUTAMONE; ANTIDEPRESSANT AGENT; CITALOPRAM; CYTOKINE; PAROXETINE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; VENLAFAXINE;

ANTIVIRAL THERAPY; ANXIETY DISORDER; AWARENESS; CHRONIC DISEASE; CONFERENCE PAPER; DEPRESSION; DRUG EFFICACY; DRUG SAFETY; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNITY; MAJOR DEPRESSION; MENTAL DISEASE; MENTAL PATIENT; MOOD CHANGE; PRACTICE GUIDELINE; PREVALENCE; PROGNOSIS; SUBSTANCE ABUSE; SYMPTOM;

EID: 84918842373     PISSN: 03535053     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (56)

1. Andreoli AV, Keller SE, Rabaeus M, Marin P, Bartlett JA & Taban C: Depression and immunity: age, severity, and clinical course. Brain Behav Immun 1993; 7:279.
2. Bezemer G, Van Gool AR, Drenth JP, Hansen BE. Fortuyn HAD, Weegink CJ, et al.: A double blind, placebo-controlled trial with escitalopram to prevent psychiatric adverse events during treatment with pegylated interferonalpha and ribavirin for chronic hepatitis C: the prevention of psychiatric side effects (Pops)-study. Hepatology, 2008.
3. Capuron L, Neurauter G, Musselman DL, Lawson DH, Nemeroff CB, Fuchs D & Miller AH: Interferon-alphainduced changes in tryptophan metabolism. Relationship to depression and paroxetine treatment. Biol Psychiatry 2003; 54-906.
4. Capuron L, Pagnoni G, Demetrashvili M, Woolwine BJ, Nemeroff CB, Berns GS & Miller AH: Anterior cingulate activation and error processing during interferonalpha treatment. Biol Psychiatry 2005; 58:190-196.
5. Capuron L, Ravaud A, Neveu PJ, Miller AH, Maes M & Dantzer R: Association between decreased serum tryptophan concentrations and depressive symptoms in cancer patients undergoing cytokine therapy. Mol Psychiatry 2002; 7-468.
6. Carta MG, Hardoy MC at al.: Association of chronic hepatitis C with major depressive disorders: irrespective of interferon-alpha therapy. Clinical Practice and Epidemiology in Mental Health, 2007.
7. Chang L, Ernst T, Witt MD, Ames N, Gaiefsky M & Miller E: Relationships among brain metabolites, cognitive function, and viral loads in antiretroviral-naive HIV patients. Neuroimage 2002; 17:1638.
8. Chang L, Lee PL, Yiannoutsos CT Ernst T, Marra CM, Richards T, Kolson D, Schifitto G, Jarvik JG, Miller EN, Lenkinski R, Gonzalez G & Navia BA: HIV MRS Consortium: A multicenter in vivo proton- MRS study of HIVassociated dementia and its relationship to age. Neuroimage 2004; 23:1336.
9. Charles L. Raison MD, Capuron L and Miller AH: Neuropsychiatric Adverse Effects of Interferon-α Recognition and Management. CNS Drugs 2005; 19:105-123.
10. Dantzer R, Connor O, Freund JC, Johnson GG & Kelley RWKW: From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci 2008; 9-46.
11. Debien C, De Chouly De Lenclave MB, Foutrein P, Bailly D: Alpha-interferon and mental disorders. Encephale. 2001; 27:308-17.
12. Diagnostic: A. A. V. V. and statistical manual of mental disorder: DSM IV TR. American Psychiatric Pub 4a ed; 2000.
13. Dieperink E, Willenbring M & Ho SB: Neuropsychiatric symptoms associated with hepatitis C and interferon alpha: a review. Am J Psychiatry 2000; 157-867.
14. European Association for the Study of the LiverEASL Clinical Practice Guidelines: Management of hepatitis C virus infection. Journal of Hepatology, 2011.
15. Forton DM, Allsop JM, Main J, Foster GR, Thomas HC & Taylor-Robinson SD: Evidence for a cerebral effect of the hepatitis C virus. Lancet 2001; 358-38.
16. Friebe A, Schwarz MJ, Schmid-Wendtner M, Volkenandt M, Schmidt F, Horn M, Janssen G & Schaefer M: Pretreatment levels of sTNF-R1 and sIL-6R are associated with a higher vulnerability for IFN-alpha-induced depressive symptoms in patients with malignant melanoma. J Immunother 1997; 30-333.
17. Galli A & Shippenberg TS: Mitogen-activated protein kinase regulates dopamine transporter surface expression and dopamine transport capacity. J Neurosci 2003; 23:8480-8488.
18. Grassi L, Satriano J, Serra A, Biancosino B, Zotos S, Sighinolfi L & Ghinelli F: Emotional stress, psychosocial variables and coping associated with haepatitis C virus and human immunodeficiency virus infections in intravenous drug users. Psychother Psychosom 2002; 71:342.
19. Gregory M, et al.: Interferon-Induced Depression in CHC. J Clin Gastroenterol 2006.
20. Horikawa N, Yamazaki T, Sagawa M & Nagata T: A case of akathisia during interferon-alpha therapy for chronic hepatitis type C. Gen Hosp Psychiatry 1999; 21:134.
21. Hussain K, Fontana R, Moyer C, Su GL, Sneed-Pee N & Lok ASF: Comorbid illness is an important determinant of health-related quality of life in patients with chronic hepatitis C. Am J Gastroenterol 2001; 96:2737.
22. Kamal SM, Ahmed A, et al.: Enhanced efficacy of pegylated interferon alpha-2a over pegylated interferon and ribavirin in chronic hepatitis C genotype 4A randomized trial and quality of life analysis. Liver Int 2011; 31:401-11.
23. Kamata M, Higuchi H, Yoshimoto M, Yoshida K & Shimizu T: Effect of single intracerebroventricular injection of alpha-interferon on monoamine concentrations in the rat brain. Eur Neuropsychopharmacol 2000; 10:129.
24. Kessler RC: Sociology and Psychiatry. In: Kaplan H.I., Sadock B.J. Comprehensive Textbook of Psychiatry. Williams & Wilkins, 1989.
25. Kitagami T, Yamada K, Miura H, Hashimoto R, Nabeshima T & Ohta T: Mechanism of systemically injected interferon-alpha impeding monoamine biosynthesis in rats: role of nitric oxide as a signal crossing the blood-brain barrier. Brain Res 2003; 978;104.
26. Leonard BE & Myint A: The psychoneuroimmunology of depression. Hum Psychopharmacol.
27. Licinio J & Wong ML: The role of inflammatory mediators in the biology of major depression: central nervous system cytokines modulate the biological substrate of depressive symptoms, regulate stressresponsive systems, and contribute to neurotoxicity and neuroprotection. Mol Psychiatry 1993; 4:317.
28. Loftis JM & Hauser P: The phenomenology and treatment of interferoninduced depression. J. Affect Disord 2004; 82:175.
29. Lotrich FE, Rabinovitz M, et al.: Depression following pegylated interferon-alpha: Characteristics and vulnerability. Journal of Psychosomatic Research 2007; 63:131.
30. Lteif GN & Mavissakalion MR: Life events and panic disorders/agoraphobia. Compreh Psychiatry, 1995.
31. Maes M, Bonaccorso S, Marino V, Puzella A, Pasquini M, Biondi M, Artini M, Almerighi C & Meltzer H: Treatment with interferon-alpha (IFN alpha) of epatiti C patients induces lower serum dipeptidyl peptidase IV activity, which is related to IFN alpha-induced depressive and anxiety symptoms and immune activation. Mol Psychiatry 2001; 6:475.
32. Majer M, Welberg LA, Capuron L, Pagnoni G, Raison CL & Miller AH: IFNalpha induced motor slowing is associated with increased depression and fatigue in patients with chronic hepatitis C. Brain Behav Immun 2008; 22:870.
33. Miller AH: Mechanisms of cytokine-induced behavioral changes: Psychoneuroimmunology at the translational interface. Brain Behavior and Immunity 2009; 23:149.
34. Morasco BJ & Rifai MA: A randomized trial of paroxetine to prevent interferon-α-induced depression in patients with hepatitis C. Journal of Affective Disorders 2007; 103:83.
35. Moron JA, Zakharova I, Ferrer JV, Merrill GA, Hope B, Lafer EM, Lin ZC, Wang JB, Javitch J. 2009; 24:165-175.
36. Musselman DL, Lawson DH, Gumnick JF, Manatunga AK, Penna S, Goodkin RS, Greiner K, Nemeroff CB & Miller AH: Paroxetine for the prevention of depression induced by high-dose interferon alpha. N Engl J Med 2001; 344:961-966.
37. Musselman DL, Miller AH, Porter MR, Manatunga AK, Gao F, Penna S, Pearce BD, Landry J, Glover S, Mcdaniel JS & Nemeroff CB: Higher than normal plasma interleukin-6 concentrations in cancer patients with depression: preliminary findings. Am J Psychiatry 2001; 158:1252.
38. Pasquini M, Speca A, et al.: Differences in depressive thougths between major depressive disorder, IFN-α-induced depression, and depressive disorders among cancer patients. Journal of Psychosomatic Research 2008; 65:153.
39. Paykel ES: The interview for recent life events. Psycol Med 1997; 27:301-310.
40. Radkowski M, Wilkinson J, Nowicki M, Adair D, Vargas H, Ingui C, Rakela J & Laskus T: Search for hepatitis C virus negative-strand RNA sequences and analysis of viral sequences in the central nervous system: evidence of replication. J Virol 2002; 76:600.
41. Raison CL, Capuron L & Miller AH: Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends Immunol 2006; 27:24.
42. Reichenberg A, Yirmiya R, Schuld A, Kraus T, Haack M, Morag A & Pollmacher T: Cytokine-associated emotional and cognitive disturbances in humans. Arch Gen Psychiatry 2001; 58: 445-452.
43. Salamone JD, Correa M, Mingote SM & Weber SM: Beyond the rewareward hypothesis: alternative functions of nucleus accumbens dopamine. Curr Opin Pharmacol 2005; 5:34.
44. Schiepers OJ, Wichers MC & Maes M: Cytokines and major depression. Prog Neuropsychopharmacol Biol Psychiatry 2005; 29:201.
45. Schultz W: Multiple dopamine functions at different time courses. Annu Rev Neurosci 2007; 30:259.
46. Shepherd J, Brodin Cave C, Waugh N, Price A & Gabbay J: Pegylated interferon-2a and-2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation. Health Technology Assessment, 2004.
47. Sockalingam S, Links PS & Abbey SE: Suicide risk in hepatitis C and during interferon-alpha therapy: a review and clinical update. J Viral Hepat 2011; 18:153-60.
48. Spiegel B, Younossi Z, Hays R, Hays RD, Revicki D, Robins S, et al.: Impact of hepatitis C on health related quality of life: a systematic review and quantitative assessment. Hepatology 2005; 41:790.
49. Thomas HC, Torok ME, Forton DM & Taylor-Robinson SD: Possible mechanisms of action and reasons for failure of antiviral therapy in chronic hepatitis C. J Hepatol 1999; 31:152-159.
50. Turnbull AV & Rivier CL: Regulation of the hypothalamic-pituitary-adrenal axis by cytokines: actions and mechanisms of action. Physiol Rev 1999; 79:1-71.
51. Ursu S, Stenger VA, Shear MK, Jones MR & Carter CS: Overactive action monitoring in obsessive-compulsive disorder: evidence from functional magnetic resonance imaging. Psychol Sci 2003; 14:347-353.
52. Wichers MC, Kenis G, Leue C, Koek G, Robaeys G & Maes M: Baseline immune activation as a risk factor for the onset of depression during interferon-alpha treatment. Biol Psychiatry 2006; 60-77.
53. Willeit M, Sitte HH, Thierry N, Michalek K, Praschak-Rieder N, Zill P, Winkler D, Brannath W, Fischer MB, Bondy B, Kasper S & Singer EA: Enhanced serotonin transporter function during depression in seasonal affective disorder. Neuropsychopharmacology 2008; 33:1503-1513.
54. Wu HQ, Rassoulpour A & Schwarcz R: Kynurenic acid leads, dopamine follows: a new case of volume transmission in the brain? J. Neural Transm 2007; 114:33-41.
55. Zhu CB, Blakely RD & Hewlett WA: The proinflammatory cytokines interleukin- 1beta and tumor necrosis factoralpha activate serotonin transporters. Neuropsychopharmacology 2006; 31:2121.
56. Zhu CB, Carneiro AM, Dostmann WR, Hewlett WA & Blakely RD: MAPK activation elevates serotonin transport activity via a traffickingindependent, protein phosphatase 2A-dependent process. J Biol Chem 2005; 280:15649.